Manager of the Stock Exchange of Thailand For the Q2/2018 period ended of June 30, 2018 (3 months) operating result of the company net loss Baht 4.32 Million comparison with the previous Q2/2017’s net loss

(1.3%) Total 283.2 292.6 (3.2%) 285.4 (0.8%) Gross Profit 57.0 65.9 (13.5%) 51.5 10.7% Net Profit/(Loss) for the year (47.7) (8.2) 481.7% (47.8) (0.2%) Net Profit/(Loss) from the period attribute to

the audited financial statements, including the consolidated financial statements of the Company and its subsidiaries for the six-month period ended 30th June 2018. The Company reported consolidated net

Baht, increasing 50.81% compared to the same period last year due to the adjustment of decremented provision and doubtful accounting policy to reflect the current assets value. 2. Cost of sales and

period last year. However, if the impact on the fluctuation of THB/USD is not taken into consideration, sales growth in this quarter would become approx. 14.7% over the same period of last year. Sales

as follows: Unit: Million Baht CONSOLIDATED FINANCIAL STATEMENTS For the three-month period ended September 30, For the nine-month period ended September 30, 2018 2017 2018 2017 REVENUES 1,200.88

Stock Exchange of Thailand For the Q3/2018 period ended of September 30, 2018 (3 months) operating result of the company net profit Baht 4.79 Million comparison with the previous Q3/2017’s net loss of

/2561 November 12, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q3/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited

: Management discussion and analysis for the period three-month ended September 30, 2018 To Director and Manager of the Stock Exchange of Thailand Referring to the submission of the reviewed financial statements

of 3.62 million Baht, decreased by 13.71 million Baht or 135.82% from the same period in last year as following details. - In this quarter, the revenue from services was 83.48 million Baht decreased